Acting director of the Center of Nuclear Medicine and Oncology, Tatyana Belikhina takes part in ESMO Immuno-Oncology Congress on December 7-9 in Geneva, Switzerland.
We remind that ESMO is the leading professional organization in the field of medical oncology. It has over 28,000 professional members from over 160 countries. ESMO Immuno-Oncology Congress is a global event that offers advanced educational program and latest scientific developments in this promising field. The participants have a chance to learn from the basics of immunotherapy to the latest research findings.
During ESMO Congress, the participants had the opportunity to update their knowledge in the rapidly developing field of cancer immunotherapy. Congress program included an overview of the current state of new diagnostic methods, biomarkers and therapeutic strategies in immuno-oncology. Recent developments in the field of immunomodulation were discussed. These included tumor microenvironment, immunometabolism, epigenetics or microbiome. New immuno-oncology strategies have also been considered. These included immune cell therapy, multispecific antibodies, oncolytic virus, or cancer vaccines.
